Recognition of Excellence
Ann Arbor, MI — November 2024 — MH3D Inc., an emerging innovator in clinical SPECT imaging technology, has been named to Renaissance Venture Capital’s 2025 Startup Hotlist. This exclusive recognition highlights MH3D as one of Michigan’s most promising startups, chosen for its innovation, growth potential, and impact on the medical imaging field.
Spotlight on UnDemo Day® and Renaissance Venture Capital
Renaissance Venture Capital’s Startup Hotlist is a carefully curated selection of companies that have garnered significant interest from investors during its UnDemo Day® events. Compiled semi-annually, the list reflects recommendations from a vast network of partners, including venture capital funds, universities, incubators, accelerators, and angel networks. MH3D’s inclusion underscores the company’s impressive progress and growing appeal within the investment community.
“Being featured on Renaissance Venture Capital’s 2025 Startup Hotlist highlights the incredible work our team has done to innovate within the field of clinical imaging and underscores the trust investors have placed in our vision,” - Xiaopei Huang, CEO of MH3D.

Looking Ahead
As MH3D continues to develop its groundbreaking SPECT platform, the company remains steadfast in its mission to improve diagnostic imaging and patient care through technological innovation. MH3D is also eager to participate in the upcoming UnDemo Day®, scheduled for April 9, 2025. This virtual event will convene leading startups and investors, fostering opportunities for collaboration and growth.
Learn More
For more information about MH3D and its innovative solutions, visit mh3dinc.com.
About MH3D Inc. MH3D Inc. is a pioneering medical imaging company based in Ann Arbor, Michigan. Specializing in cutting-edge SPECT technology, MH3D aims to improve patient care and advance scientific research through innovative solutions. A spinout from the University of Michigan, Ann Arbor, and the University of Illinois, Urbana-Champaign, MH3D is at the forefront of transforming imaging technology for clinical and pre-clinical applications.
Comments